More than 10% of U.S. adults now use GLP-1 medications like Ozempic and Wegovy, but a significant portion – roughly 14% of users – are not taking standard doses. Instead, they’re engaging in microdosing : injecting tiny portions of the drug. While some do this to lower costs, others believe that smaller doses can unlock the drugs’ health benefits without the full weight loss or side effects.
This trend reflects a growing interest in longevity hacking —the pursuit of extending lifespan and healthspan through unconventional means. GLP-1 drugs, originally designed for type 2 diabetes and obesity, mimic a natural hormone that regulates appetite, metabolism, and blood sugar. Emerging research suggests these drugs may offer broader benefits, including reduced inflammation, lower cardiovascular risk, and even potential protection against age-related diseases like Alzheimer’s. This is why some companies, such as AgelessRx, now explicitly market GLP-1 microdoses as a path to “long-term wellness.”
The Science Behind the Hype
While rigorous scientific data on microdosing is still lacking, preliminary studies offer intriguing hints. One study in JAMA Psychiatry found that low doses of semaglutide (the active ingredient in Ozempic/Wegovy) might reduce alcohol cravings. AgelessRx is currently conducting its own clinical trial on the effects of microdosing on health and quality of life.
Some physicians are already integrating microdosing into their practice. Dr. Shamsah Amersi, an ob-gyn in Santa Monica, reports that 60% of her patients over 40 use GLP-1 microdoses, citing improved metabolic health and overall well-being. She argues that patients can benefit now, even without definitive proof, if closely monitored by a healthcare professional.
Skepticism and Risks Remain
Not all experts are convinced. Clinical pharmacist Anne Komé cautions that the benefits of microdosing are unproven, while bariatric medicine specialist Katy Williams emphasizes that focusing on diet, exercise, and sleep remains the safest path to longevity. The lack of long-term data raises concerns about potential unknown risks.
“There isn’t enough data to confirm that microdosing can help you live longer…It’s not worth taking that chance when benefits are unproven.”
– Katy Williams, University of Missouri Health Care
The rise of GLP-1 microdosing highlights a broader trend: individuals taking control of their health through experimental, often off-label, interventions. While the potential benefits are intriguing, proceeding with caution and under medical supervision remains crucial. The drugs are not without risks, and the long-term consequences of microdosing are still unknown.
